Gefitinib (Gef), as a first-generation reversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), has been confirmed to provide clinical benefits to NSCLC patients with activating EGFR mutations2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.